Gulisa Turashvili, Anthony N Karnezis, Keren I Hulkower, Colleen Hebert, Lara Harik, Barbara Crothers, Giovanna Giannico, Kristin K Deeb, Krisztina Hanley, Raji Ganesan, Anne Mills, Natalia Buza
{"title":"报告妇科起源癌患者标本的生物标志物检测结果：更新的美国病理学家学会协议。","authors":"Gulisa Turashvili, Anthony N Karnezis, Keren I Hulkower, Colleen Hebert, Lara Harik, Barbara Crothers, Giovanna Giannico, Kristin K Deeb, Krisztina Hanley, Raji Ganesan, Anne Mills, Natalia Buza","doi":"10.5858/arpa.2025-0157-CP","DOIUrl":null,"url":null,"abstract":"<p><strong>Context.—: </strong>The first version of the Template for Reporting Results of Biomarker Testing of Specimens From Patients With Carcinoma of Gynecologic Origin (hereafter referred to as the Gynecologic Biomarker Protocol) was released by the College of American Pathologists (CAP) in 2022. Minor updates included clarification of the content of p53 status and explanatory notes for human epidermal growth factor receptor 2 (HER2) and mismatch repair testing in 2023. Recent developments in biomarker testing have prompted a major update to this protocol, published in December 2024.</p><p><strong>Objective.—: </strong>To assess prognostic and/or therapeutic markers since the release of the 2023 Gynecologic Biomarker Protocol and to update testing recommendations in gynecologic carcinomas, with expanded explanatory notes and illustrative examples provided in this article.</p><p><strong>Design.—: </strong>The CAP Cancer Committee assembled a panel of experts subspecialized in gynecologic pathology to augment the existing biomarkers, add new biomarkers, expand test reporting, and revise explanatory notes based on available evidence and clinical practice guidelines such as those of the American Society of Clinical Oncology/CAP, National Comprehensive Cancer Network, and Society for Immunotherapy of Cancer.</p><p><strong>Results.—: </strong>The changes to the Gynecologic Biomarker Protocol include updates to hormone receptors and addition of subclonal loss of mismatch repair proteins, subclonal abnormal p53 expression, programmed death ligand-1 (PD-L1) testing, and folate receptor alpha testing, as well as updates to HER2 testing and all explanatory notes.</p><p><strong>Conclusions.—: </strong>The updated CAP Gynecologic Biomarker Protocol provides improved structure and clarity in the reporting of prognostic and/or therapeutic biomarkers and comprehensive explanatory notes that aid in understanding the rationale for testing, interpretive guidance, and common testing pitfalls, based on the current standard of care.</p>","PeriodicalId":93883,"journal":{"name":"Archives of pathology & laboratory medicine","volume":" ","pages":""},"PeriodicalIF":3.2000,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Reporting Results of Biomarker Testing of Specimens From Patients With Carcinoma of Gynecologic Origin: The Updated College of American Pathologists Protocol.\",\"authors\":\"Gulisa Turashvili, Anthony N Karnezis, Keren I Hulkower, Colleen Hebert, Lara Harik, Barbara Crothers, Giovanna Giannico, Kristin K Deeb, Krisztina Hanley, Raji Ganesan, Anne Mills, Natalia Buza\",\"doi\":\"10.5858/arpa.2025-0157-CP\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Context.—: </strong>The first version of the Template for Reporting Results of Biomarker Testing of Specimens From Patients With Carcinoma of Gynecologic Origin (hereafter referred to as the Gynecologic Biomarker Protocol) was released by the College of American Pathologists (CAP) in 2022. Minor updates included clarification of the content of p53 status and explanatory notes for human epidermal growth factor receptor 2 (HER2) and mismatch repair testing in 2023. Recent developments in biomarker testing have prompted a major update to this protocol, published in December 2024.</p><p><strong>Objective.—: </strong>To assess prognostic and/or therapeutic markers since the release of the 2023 Gynecologic Biomarker Protocol and to update testing recommendations in gynecologic carcinomas, with expanded explanatory notes and illustrative examples provided in this article.</p><p><strong>Design.—: </strong>The CAP Cancer Committee assembled a panel of experts subspecialized in gynecologic pathology to augment the existing biomarkers, add new biomarkers, expand test reporting, and revise explanatory notes based on available evidence and clinical practice guidelines such as those of the American Society of Clinical Oncology/CAP, National Comprehensive Cancer Network, and Society for Immunotherapy of Cancer.</p><p><strong>Results.—: </strong>The changes to the Gynecologic Biomarker Protocol include updates to hormone receptors and addition of subclonal loss of mismatch repair proteins, subclonal abnormal p53 expression, programmed death ligand-1 (PD-L1) testing, and folate receptor alpha testing, as well as updates to HER2 testing and all explanatory notes.</p><p><strong>Conclusions.—: </strong>The updated CAP Gynecologic Biomarker Protocol provides improved structure and clarity in the reporting of prognostic and/or therapeutic biomarkers and comprehensive explanatory notes that aid in understanding the rationale for testing, interpretive guidance, and common testing pitfalls, based on the current standard of care.</p>\",\"PeriodicalId\":93883,\"journal\":{\"name\":\"Archives of pathology & laboratory medicine\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2025-09-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Archives of pathology & laboratory medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5858/arpa.2025-0157-CP\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of pathology & laboratory medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5858/arpa.2025-0157-CP","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Reporting Results of Biomarker Testing of Specimens From Patients With Carcinoma of Gynecologic Origin: The Updated College of American Pathologists Protocol.
Context.—: The first version of the Template for Reporting Results of Biomarker Testing of Specimens From Patients With Carcinoma of Gynecologic Origin (hereafter referred to as the Gynecologic Biomarker Protocol) was released by the College of American Pathologists (CAP) in 2022. Minor updates included clarification of the content of p53 status and explanatory notes for human epidermal growth factor receptor 2 (HER2) and mismatch repair testing in 2023. Recent developments in biomarker testing have prompted a major update to this protocol, published in December 2024.
Objective.—: To assess prognostic and/or therapeutic markers since the release of the 2023 Gynecologic Biomarker Protocol and to update testing recommendations in gynecologic carcinomas, with expanded explanatory notes and illustrative examples provided in this article.
Design.—: The CAP Cancer Committee assembled a panel of experts subspecialized in gynecologic pathology to augment the existing biomarkers, add new biomarkers, expand test reporting, and revise explanatory notes based on available evidence and clinical practice guidelines such as those of the American Society of Clinical Oncology/CAP, National Comprehensive Cancer Network, and Society for Immunotherapy of Cancer.
Results.—: The changes to the Gynecologic Biomarker Protocol include updates to hormone receptors and addition of subclonal loss of mismatch repair proteins, subclonal abnormal p53 expression, programmed death ligand-1 (PD-L1) testing, and folate receptor alpha testing, as well as updates to HER2 testing and all explanatory notes.
Conclusions.—: The updated CAP Gynecologic Biomarker Protocol provides improved structure and clarity in the reporting of prognostic and/or therapeutic biomarkers and comprehensive explanatory notes that aid in understanding the rationale for testing, interpretive guidance, and common testing pitfalls, based on the current standard of care.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
